Nektar Therapeutics Stock Analysis & AI Score
Nektar Therapeutics (NKTR) has an ST Score of 55.5 (B-), driven by its Forecast (A) and held back by its Momentum (C). Analysts rate it Buy with a $145.00 price target (+144.2% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Nektar Therapeutics (NKTR) has an ST Score of 55.5 (B-), driven by its Forecast (A) and held back by its Momentum (C). Analysts rate it Buy with a $145.00 price target (+144.2% upside).
- Strongest
- ForecastA
- Weakest
- MomentumC
All factor grades
- ForecastA
- ProfitabilityA-
- ValuationB
- Financial StrengthB
- GrowthC+
- MomentumC
- Piotroski1/9
Contact
NKTR stock: frequently asked questions
What is NKTR's ST Score?
Nektar Therapeutics (NKTR) has an ST Score of 55.5 (B-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is NKTR a buy, hold, or sell?
Analysts rate NKTR a Buy, with a price target of $145.00 (+144.2% vs the current price). Our ST Score grades it B- (55.5/100). The ST Score is a data-driven signal, not a recommendation.
What are NKTR's factor grades?
Valuation B, Profitability A-, Financial Strength B, Momentum C, Growth C+, Forecast A.
What is NKTR's valuation grade?
Nektar Therapeutics (NKTR) earns a valuation grade of B, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is NKTR's growth grade?
Nektar Therapeutics (NKTR) earns a growth grade of C+, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is NKTR's profitability grade?
Nektar Therapeutics (NKTR) earns a profitability grade of A-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is NKTR's financial strength grade?
Nektar Therapeutics (NKTR) earns a financial strength grade of B, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for NKTR?
The average analyst price target for Nektar Therapeutics (NKTR) is $145.00 from 33 analysts, which is +144.2% versus the recent price of $59.38.
What is NKTR's Piotroski score?
Nektar Therapeutics (NKTR) has a Piotroski F-Score of 1 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.